128 related articles for article (PubMed ID: 329981)
1. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
[No Abstract] [Full Text] [Related]
3. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
4. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
Everall JD; Dowd PM
Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710
[No Abstract] [Full Text] [Related]
5. Results with methyl-CCNU and DTIC in metastatic melanoma.
Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
[TBL] [Abstract][Full Text] [Related]
6. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; Eagan RT; O'Connell MJ; Frytak S
Clin Pharmacol Ther; 1976 Jun; 19(6):821-4. PubMed ID: 773589
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
8. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of metastatic malignant melanoma (author's transl)].
Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
[TBL] [Abstract][Full Text] [Related]
10. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Carmo-Pereira J; Oliveira Costa F; Pimentel P
Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
[No Abstract] [Full Text] [Related]
11. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
12. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
13. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
De Wasch G; Bernheim J; Michel J; Lejeune F; Kenis Y
Cancer Treat Rep; 1976 Sep; 60(9):1273-6. PubMed ID: 65222
[TBL] [Abstract][Full Text] [Related]
15. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
[TBL] [Abstract][Full Text] [Related]
17. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
18. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
Chauvergne J; Clavel B; Klein T; Pommatau E
Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
[TBL] [Abstract][Full Text] [Related]
19. A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas.
Creagan ET; Hahn RG; Ahmann DL; Edmonson JH; Bisel HF; Eagan RT
Cancer Treat Rep; 1976 Sep; 60(9):1385-7. PubMed ID: 189922
[No Abstract] [Full Text] [Related]
20. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Johnson RO; Metter G; Wilson W; Hill G; Krementz E
Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]